You have matched to 1 trials

Guest Profile:  No profile selected

Why register? Save your profile, save trials, and enter treatment history for more accurate matching.
1

Targeted Therapy for People with Brain Metastases with MET Mutations

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors <span class="highlight"></span>

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of tepotinib (Tepmetko®) c-Met inhibitor alone or with osimertinib (Tagrisso®) EGFR inhibitor.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Your brain tumor must have a MET mutation. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tepotinib (Tepmetko®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tepotinib (Tepmetko®), by mouth</li> <li class="seamTextUnorderedListItem">Osimertinib (Tagrisso®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tepotinib (Tepmetko®) is a type of targeted therapy called a c-Met inhibitor. Blocking c-Met may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Osimertinib (Tagrisso®) is a type of targeted therapy called an EGFR inhibitor. Blocking EGFR may help slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Tepotinib (Tepmetko®) and osimertinib (Tagrisso®) are approved for the treatment of other cancers, so their use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid that surrounds your brain and spinal cord. CSF will be collected during a procedure called a lumbar puncture, also known as a spinal tap.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: MET</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05120960' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a621012.html' target='_blank'>Medline Plus: Tepotinib (Tepmetko®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a616005.html#:~:text=Osimertinib%20is%20used%20to%20help,of%20the%20body%20in%20adults.' target='_blank'>Medline Plus: Osimertinib (Tagrisso®)</a> </li></ul>
1

Targeted Therapy for People with Brain Metastases with MET Mutations

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors <span class="highlight"></span>
Icon

Nearest Location:
1643 miles
M D Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05120960

Icon

Phase I